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Abstract 
 
 The aim of this study was to elucidate the oxidation products of a candidate 
antimalarial drug, PL69, using a porphyrin system and to determine the accuracy of the 
oxidation products produced, as compared to what is expected in metabolism.  PL69 is a 
reversed chloroquine (RCQ) that is active against chloroquine resistant malaria.  
Porphyrin oxidation systems have been shown to mimic in vitro enzymatic metabolism 
reactions.  PL69 and its known metabolite, PL16, were incubated with the porphyrin 
system, and then the oxidation products were collected and separated by HPLC.  The 
oxidation products were characterized by NMR and mass spectrometry and compared 
to previous metabolism studies of PL69 with liver microsomes.  The results of this 
research show that this porphyrin system is an acceptable mimic of in vitro metabolism 
methods for RCQs and provides a good framework for understanding the types of 
metabolism that will occur in vivo for RCQs.     
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Introduction 
 
Malaria is a significant issue throughout the world, affecting the lives of many 
people.  In 2012, 207 million people were infected with malaria, and 627,000 of those 
infections resulted in death.  Sub-Saharan Africa is the region most affected by malaria, 
accounting for 90% of the deaths related to malaria (“10 Facts on Malaria”, 2014).  The 
physical effects of malaria include fevers, headaches, vomiting, disruption of blood 
supply, and, possibly, death (Malaria, 2014).  Malaria affects a person physically, but in 
endemic areas, also severely affects the country’s economy due to debilitating cyclic 
effects during infection, rendering a person unable to work consistently (Gallup, 2001).  
Human malaria is caused by five different species of Plasmodiae; Plasmodium ovale, 
malariae, knowlesi, vivax, and falciparum.  P. falciparum accounts for 95% of deaths 
caused by malaria, and is therefore the most heavily researched (Roepe, 2009).   
The malaria parasite is transmitted via the female Anopheles mosquito.  When 
the mosquito takes a blood meal, sporozoites are injected from the mosquito into the 
host and go straight to the liver cells to multiply (Figure 1, #1-2).  These sporozoites then 
invade the host erythrocytes and go through a process of reproduction called 
schizogony, producing merozoites (Figure 1, #3-4).  The production of many merozoites 
then bursts the red blood cells allowing the merozoites to infect other erythrocytes.  
Merozoites that infect erythrocytes can differentiate into male and female gametocytes 
which can then be taken up by a mosquito (Figure 1, #5-6).  Sexual reproduction occurs 
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in the mosquito forming more sporozoites to be transmitted to other hosts (Figure 1, 
#7-9) (Sherman, 2005).   
 
A common method of treating malaria is to inhibit Plasmodium at the merozoite 
stage to prevent rupturing of the erythrocytes, so the merozoites cannot further infect 
more erythrocytes.  The parasites in the red blood cells digest hemoglobin in their 
digestive vacuole (DV) to obtain needed amino acids, releasing free heme 
Figure 1: The life cycle of the Plasmodium parasite (Klein, 2013) 
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(ferriprotoporphyrin IX) (Pishchany, 2012).  Heme is toxic to the parasite because it does 
not have the heme oxygenase pathway, so it forms hemozoin (Roepe, 2009).  Hemozoin 
is crystallized heme that forms in the digestive vacuole of the parasite because the pH of 
the digestive vacuole is about 5.2 and heme precipitates as hemozoin below pH 5.4 
(Kuhn, 2007).  As it crystallizes, hemozoin deposits in the gut of the parasite, which is 
the cause of the characteristic black granules in erythrocytes infected with malaria.  
Rupturing of the red blood cells releases the merozoites as well as hemozoin.  This stage 
of the Plasmodium lifecycle is what causes the symptoms commonly associated with 
malaria.  
Inhibiting formation of hemozoin has been a target for many antimalarial drug 
therapies, and is the method of action for one of the most widely known and used 
antimalarial drugs, chloroquine (CQ) (Figure 2).  CQ was put in to use shortly after WWII 
and was very successful because it was effective, inexpensive, and safe for children and 
pregnant women (Wellems, 2001).  CQ is active against P. falciparum through 
interactions with heme in the digestive vacuole of the parasite.  There is a large 
accumulation of CQ in the digestive vacuole in part because of a pH gradient between 
the cytoplasm of the red blood cells, the cytoplasm of the parasite, and the digestive 
vacuole.  The red blood cell and parasite cytoplasm are very similar in pH, about 7.1.  At 
this pH, CQ has a +1 charge and is able to freely move through the cell membranes all 
the way into the digestive vacuole (Chinappi, 2010).  The pH of the digestive vacuole is 
about 5, which makes CQ have a 2+ charge.  Because of this large pH difference and 
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formation of the doubly charged species, CQ is able to accumulate in the DV much 
higher than in the cytoplasm (Kuhn, 2007).  In the digestive vacuole, CQ interacts with 
heme, preventing the formation of hemozoin, eventually killing the parasite (Roepe, 
2009).  The exact method of inhibition by CQ is not known, but it is believed that CQ 
might affect the pH of the DV, therefore affecting the heme polymerization.  Another 
idea is that CQ binds directly to heme, preventing development of a crystal (Roepe, 
2009).  
 
 
Despite the effectiveness of CQ, there is increasing worldwide resistance to CQ 
as well as to many other antimalarial drugs.  The digestive vacuole of the CQ-sensitive 
and -resistant P. falciparum has a membrane transporter called the P. falciparum 
chloroquine resistance transporter (PfCRT), which is partly responsible for the increasing 
resistance to chloroquine.  Resistant parasites have been found to have a mutated 
version of the pfcrt gene, causing mutations in the protein sequence that allows the 
parasite to move CQ out of the digestive vacuole.  With CQ at a reduced DV 
Chloroquine (CQ) 
Figure 2: The structure of CQ. 
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concentration, hemozoin is once again formed allowing the parasite to survive 
(Chinappi, 2010).  
CQ resistance isn’t caused by just one mutation of a nucleic acid in the pfcrt 
gene, but by many mutations.  Outlined in Table 1 are the various strains of CQ-resistant 
P. falciparum and the mutations of amino acids that lead to resistance.  It is important 
to note that there isn’t just one strain of CQ-resistant malaria that spread across the 
world, but rather resistance to CQ developed independently in different parts of the 
world, with different types of mutations leading to the resistance.  A common mutation 
in all the strains listed in the table is a change from lysine at the 76 position to 
threonine.  The CQ-sensitive strain labeled 106/1 has many of the same mutations as 
the resistant strands, except it doesn’t have the mutation at the 76 position.  This 
indicates that mutating the positively charged lysine to an uncharged threonine is a key  
mutation in resistance to CQ (Wellems, 2001). 
 PfCRT position and encoded amino acid 
Parasite type and origin 72 74 75 76 97 220 271 326 356 371 
CQ-sensitive           
     Wild type C M N K H A Q N I R 
     106/1 C I E K H S E S I I 
CQ-resistant           
     SE Asia and Africa, type E1a C I E T H S E S T I 
     SE Asia and Africa, type E1b C I E T H S E S I I 
     Papua New Guinea, type P1 S M N T H S Q D L R 
     South America, type W1a S M N T H S Q D L R 
     South America, type W1b C M N T H S Q D L R 
     South America, type W2 C M E T Q S Q N I T 
Table 1: Comparison of key amino acids in CQ-sensitive and CQ-resistant strains of P. falciparum as 
well as where the resistant strains originated. 
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The increasing resistance of P. falciparum to CQ, leads to a need for more 
potent, cost effective drugs that are active against this parasite.  A new drug, PL69, has 
been synthesized that is a “reversed chloroquine” (RCQ), which combines chloroquine 
with a reversal agent (Figure 3).  Reversal agents are molecules that reverse resistance 
to drugs; in this case, reversing resistance to chloroquine.  Reversal agents can be taken 
with a drug as a cocktail or can be combined with the drug molecule to make a new 
drug, which is what was done in the case of PL69.  The reversal agent on PL69 reduces 
the efflux of the chloroquine-like drug from the digestive vacuole, reversing the 
parasite’s resistance (Burgess, 2010).  The IC50 values of CQ and PL69 for a CQ-sensitive 
strain and a CQ-resistant strain are listed in Table 2.  These IC50 values refer to the 
concentration of drug needed to inhibit growth of the Plasmodium by 50%.  PL69 has a 
lower IC50 than CQ against the sensitive strain as well as has a very low IC50 against the 
resistant strain, showing that PL69 reverses CQ resistance (Andrews, 2010). 
 
 
 
 
CQ-like portion Reversal agent portion 
Figure 3: Structure of PL69, a reversed chloroquine, indicating the CQ-like 
and reversal agent portions of the molecule 
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 IC50 (nM) 
Compound D6 (sensitive) Dd2 (resistant) 
CQ 7 102 
PL69 1.6 1.8 
 
 As drugs are developed, their metabolism products need to be identified quickly 
and early in the drug discovery process.  There are multiple reasons as to why it is 
important to elucidate drug metabolism products, including to determine toxicity, 
efficacy, and pharmacokinetics of the metabolites. There are three phases in drug 
metabolism, commonly listed as phase I, phase II, and phase III.  Phase I is mostly done 
by the cytochromes P450 and makes the substrate more water soluble.  This usually 
occurs by some sort of oxidation, but can also occur through N-dealkylation, hydrolysis, 
demethylation, etc.  In phase II, the oxidized substrate is conjugated to a charged 
species.  Phase II processes include glucuronidation, sulfation, glutathione conjugation, 
and methylation.  Phase III consists of elimination of the xenobiotic from the body 
(Jurva, 2003).   
Human phase I drug metabolism takes place mostly in the liver, but also can 
occur in the digestive tract.  In humans, there are 75 different isozymes of CYP450 with 
a large majority of these being embedded in membranes (Danielson, 2002).  The liver 
has other enzymes involved in metabolism, but 75% of phase I drug metabolism is done 
Table 2: IC50 values of CQ and PL69 for a CQ-sensitive and a CQ-resistant strain of 
P. falciparum (Andrews, 2010). 
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by CYP450s.  Of those CYPs, almost half of the metabolism is done by just three 
isozymes, CYP3A4, 5, and 7.  There is a cofactor that is consistent in all CYP450s, which is 
iron(III)protoporphyrin IX, or heme (Woggon, 2007).  This porphyrin cofactor is the 
reactive center of the CYP450s, producing the active species by binding to molecular 
oxygen.  The general reaction catalyzed by CYP450 is shown in the following equation, 
with “SH” signifying substrate: 
NAD(P)H + O2 + SH + H+  NAD(P)+ + SOH + H2O 
The role of CYP450 in drug metabolism is to activate oxygen, which can then 
attack the substrate, introducing more polar functionality, making it more water soluble 
(Danielson, 2002).  The main reaction of CYP450s that is discussed in literature is 
hydroxylation (shown above), but there are many other reactions catalyzed by this 
enzyme. These other reactions include, but are not limited to, deamination, 
epoxidation, S-, N-, and O-dealkylations, and dehalogenations. 
It is not often easy to determine the identity of metabolites, but it is important 
to do so.  Looking at the pharmacokinetics allows the identification of what CYP is 
involved in metabolism to help in determining drug-drug interactions as well as knowing 
how fast the drug is degraded.  There are multiple methods to examine metabolism, 
some easier and cheaper than others.  Even though many of the products are the same, 
they are produced in various amounts and sometime there are more or less metabolites 
9 
 
depending on the method.  The next section will discuss the most common types of in 
vitro metabolism as well as chemical mimics of enzymatic oxidations. 
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Mimicking in vivo Metabolism 
 
There are many new drug candidates being synthesized every day and in order 
for the drug to advance in clinical trials, the metabolites need to be identified and any 
toxicity made to be evaluated.  There are a few ways of identifying metabolites, but the 
current methods usually include using hepatocytes or liver microsomes.  Microsomes 
are vesicle-like structures formed upon homogenization of the liver and differential 
high-speed centrifugation.  During homogenization and centrifugation, the CYP450 
enzymes become very concentrated in these vesicles, making them desirable for 
analysis of metabolites (Baranczewski, 2006).  Hepatocytes and microsomes give fairly 
accurate in vitro depictions of the type of transformations the drug will undergo.  
However, there are some downsides to using these methods.  Both hepatocytes and 
microsomes must be extracted from an organism and kept frozen, leading to a high cost 
for every drug incubation.  Another downside of using these in vitro methods is that the 
enzymes don’t remain active for very long and it is often difficult to obtain enough 
product for complete analysis of the metabolites.   
In order to minimize costs of examining the metabolites formed, there has been 
an increasing amount of research on chemical mimics of CYP450 systems.  These mimics 
include an electrochemical system using the Fenton reaction, and using 
metalloporphyrins to mimic the heme cofactor present in CYP450s.  The Fenton reaction 
involves using an electrochemical cell to reduce Fe3+ to Fe2+, which then reacts with 
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hydrogen peroxide, generating hydroxyl radicals and Fe3+ (Figure 4).  The 
electrochemical cell then reduces the iron, regenerating Fe2+ and starting the oxidation 
process over.  The hydroxyl radicals can add to aromatic rings and double bonds causing 
oxidation such as what would be seen with CYP450 (Johansson, 2007). 
 
A study to compare electrochemical oxidation products with those formed in 
CYP450 reactions was done by Ulrik Jurva (Jurva, 2003).  The results of that study 
showed that the products of the electrochemical oxidation were often the same as 
those seen in the enzyme catalyzed reactions.  The reactions that were found to work by 
this method were one-electron oxidations such as N-dealkylation, alcohol oxidation, and 
dehydrogenation.  Hydrogen atom abstraction reactions had too high of oxidation 
potentials, and include reactions such as O-dealkylation and hydroxylation of 
unsubstituted aromatic rings.  Even though the method using electrochemical oxidation 
does not fully mimic the type of oxidations of the CYP450 enzymes, it is a good model to 
examine oxidation products to propose the type of products that may be formed by 
microsomes or hepatocytes (Jurva, 2003). 
Another model system to study drug oxidation involves mimicking part of the 
active site of CYP450s, rather than just mimicking their oxidation reactions.  The active 
site of CYP450 has an iron protoporphyrin IX, which creates active species of oxygen 
that cause the oxidation processes.  Research is ongoing using metalloporphyrins as 
                    e- 
 
Fe2+ + H2O2  Fe3+ + OH- + ·OH 
 
Figure 4: The electrochemical Fenton reaction 
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mimics of the CYP450 active site, heme.  The most useful CYP-mimicking porphyrins are 
water soluble metalloporphyrins, which can more closely mimic the environment in 
which metabolism occurs, as compared to metalloporphyrins that are only soluble in 
organic solvents (Bernadou, 1990).  Metalloporphyrins have the same benefits as the 
electrochemical systems, as compared to microsomes and hepatocytes, except the 
system does not regenerate itself.  Research has been done on various types of 
metalloporphyrins, including changing the metal ions and attaching different groups to 
the porphyrins (Johansson, 2007).   
There are quite a few instances showing that metalloporphyrin oxidations can 
mimic CYP reactions when added in conjunction with an oxygen donating compound, 
such as hydrogen peroxide.  A study done by J. Bernadou compared the activity of 
various metalloporphyrins to horse radish peroxidase (HRP), which has a heme group in 
the active site (Bernadou, 1990).  Four metalloporphyrins were used: iron(III) and 
manganese (III) tetrasodium meso-tetrakis(p-sulfonatophenyl)porphyrin [Fe(III)TPPS 
(Figure 5) and Mn(III)TPPS, respectively], and iron(III) and manganese(III) tetraacetate 
meso-tetrakis(4-N-methylpyridiniumyl)porphyrin [Fe(III)TMPyP and Mn(III)TMPyp, 
respectively].  Oxidation of acetaminophen by these four metalloporphyrins and HRP 
were examined, because the oxidation product of acetaminophen is known.  The 
metalloporphyrins and HRP all produced the desired metabolite, N-acetyl-p-
benzoquinone-imine (NAPQI) with varying rates and yields.  Both Fe(III)TPPS and HRP 
had initial turnover rates that were too fast to be measured.  The amount of NAPQI 
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produced by Fe(III)TPPS (88% yield) was higher than the other metalloporphyrins, as 
well as higher than HRP (40-50% yield).  The other metalloporphyrins transformed 
between 20 and 50% of acetaminophen to NAPQI, which at the high range is 
comparable to the amount of product produced by HRP (Bernadou, 1990).  This study is 
a good indicator of how metalloporphyrins can be mimics of an oxidizing enzyme. 
 
 
Another study compared the products produced by oxidizing metoprolol with 
human and rat liver microsomes, the electrochemical Fenton reaction, and a 
metalloporphyrin system using Fe(III)TPPS (Figure 5) (Johansson, 2007).  The products 
were examined using liquid chromatography coupled with a mass spectrometer (LCMS).  
Looking at the LC chromatograms, there were seven products produced by rat liver 
microsomes, and four produced by human liver microsomes.  The electrochemical 
Figure 5: Structure of iron (III) tetrasodium meso-tetrakis(p-sulfonatophenyl)porphyrin. 
 
14 
 
Fenton reaction produced five of the same products as the rat microsomes and the 
porphine system produced six of the seven products.  The products were also analyzed 
by mass spectrometry in order to be sure the peaks seen in the chromatograms were 
the same.  Between each method, there was variation in the amounts of products 
produced, but both methods formed the major metabolites seen in the microsome 
systems.  This research group analyzed the oxidation products of other drugs to 
compare the products of each system, as well as to determine the mimic system that 
best executed each type of reaction, the results of which are shown in Table 3.  The 
porphine system was recommended as a mimic for many of the enzymatic oxidations, 
including N-dealkylation, alcohol oxidation, and aliphatic hydroxylation (Johansson, 
2007).  
Enzymatic Oxidation Recommended System 
Aliphatic hydroxylation EC-Fenton or porphine 
Benzylic hydroxylation EC-Fenton or porphine 
Aromatic hydroxylation EC-Fenton or porphine 
N-dealkylation EC-Fenton or porphine 
N-oxidation Porphine 
O-dealkylation Porphine 
Alcohol oxidation Porphine 
Aldehyde oxidation Porphine 
Deydrogenation EC-Fenton or porphine 
 Table 3: The recommended systems for mimicking various enzymatic oxidations (Johansson, 2007). 
15 
 
While the electrochemical system seems effectively to mimic enzymatic 
oxidation, there is more equipment needed to use it.  The easier use of 
metalloporphyrins and more readily available equipment led to the use of Fe(III)TPPS for 
the research done in this thesis.  Rat liver microsomes were also used to compare the 
products of metabolism to the oxidative products from the porphine system.    
 
Based on the literature of the metalloporphyrins oxidations, it was hypothesized 
that there could be N-dealkylation at the amine linkages in PL69 (Figure 6), aromatic 
hydroxylation, or hydroxylation on the aliphatic carbon chain or piperidine.  A metabolic 
study was done on PL69 by WuXi AppTec, but the only type of analysis done on the 
products was LC-MS.  In order to fully understand the products formed, NMR analysis 
needed to be done, which was the main method of elucidation used in this thesis.  The 
incubations done with both methods had to be done in sufficiently large quantities in 
order to obtain enough product formation to be analyzed by NMR.   
 The metabolism of PL69 in human, rat, and liver microsomes was analyzed 
through mass spectrometry by WuXi AppTec, a bio analytical company based in China.  
Figure 7 shows the proposed structures for the metabolites produced in the highest 
Figure 6: structure of PL69 - a reversed chloroquine 
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amounts.  The percent formation in human liver microsomes is listed after the 
molecular weights.  Table 4 lists the percent formation of each metabolite in rat, 
monkey, and human liver microsomes.  Many of the proposed metabolism products are 
results of N-dealkylation and/or oxygenation.  M1 and M3 were produced in the highest 
amounts in the human microsomes, 14.26% and 21.30%, respectively, as measured by 
LCMS.  M1 and M3 were also produced in high amounts in the rat and monkey 
microsomes (Table 4).  The relative abundance was calculated by the areas of the parent 
and metabolite peaks on the mass spectrum.  There were some metabolites not 
produced in the human microsomes that were produced in the either the monkey or rat 
microsomes, but many of the high yield metabolites were produced with the 
microsomes of all three species.  Mass spectrometry provides an accurate mass and 
general picture of what the molecule might look like based on the mass, but without 
other structural analysis, mostly by NMR, the complete structures will not be known.   
 
Metabolite 
Relative Abundance (%) 
human liver microsomes 
monkey liver 
microsomes 
rat liver microsomes 
M1 14.26 7.18 15.13 
M2 8.20 3.26 15.97 
M3 21.30 36.20 18.95 
M4 n/a 1.22 n/a 
M5 8.40 5.05 0.83 
M6 5.80 3.68 1.85 
M7 n/a 1.91 n/a 
M8 6.48 10.48 4.25 
M9 0.85 n/a 4.58 
M10 0.58 n/a n/a 
Table 4: Percentage of metabolites found from incubation with rat, monkey, and human liver 
microsomes.  This data was determined by WuXi AppTec.  Structures of these metabolites are in 
Figure 7. 
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Figure 7: The proposed metabolism of PL69 using human liver microsomes.  The metabolite 
molecular weight and the percentage formed are listed under the structures. 
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Methods 
 
The antimalarial compound, PL69 (Figure 8), was analyzed using microsomes and 
iron(III)meso-tetrakis(p-sulfonatophenyl)porphyrin (Fe(III)TPPS) to examine the 
oxidations that mimic in vivo metabolic reactions.  The resulting products were 
separated and analyzed using HPLC, NMR, and mass spectrometry.    
Microsomal Incubations -Rat liver microsomes and an NADPH regenerating system were 
purchased from BD Biosciences.  The rat liver microsomes were harvested from male 
Sprague-Dawley rats and were in a concentration of 20 mg/mL in a 250 mM sucrose 
solution.  The NADPH regenerating system consisted of two solutions, Solution A (26 
mM NADP+, 66 mM glucose-6-phosphate, and 66 mM MgCl2 in H2O) and Solution B (40 
U/mL glucose-6-phosphate dehydrogenase in 5 mM sodium citrate).  The method for 
doing the microsomal incubations was adapted from the procedure provided by BD 
Biosciences upon purchase of the microsomes.   
There was a small scale incubation (0.5 mL total) of PL69 with the microsomes and then 
the method was scaled up.  The large scale method consisted of the following final 
concentrations (final volume of 5 mL): 50 uM PL69, 100 mM phosphate buffer (pH 7.4), 
0.5 mg/mL rat liver microsomes, 20x dilution of NADPH solution A, and 100x dilution of 
NADPH solution B.  Everything but the microsomes were added, which were added after 
the solution was in a 37oC water bath for 5 minutes.  The solution was then incubated 
for 60 minutes in the 37oC water bath.  After 60 minutes, the solution was then put on 
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ice, and ice cold acetonitrile was added to halt the enzyme activity and precipitate the 
proteins.  The solution was then centrifuged and the supernatant collected.  The 
products were extracted by raising the pH to above 10 and extracting with 
dichloromethane (DCM).   
Porphyrin incubations – Porphyrin incubations were done on both PL69 and PL16 (Figure 
8), because PL16 is known from the microsomal incubations as well as other studies to 
be a metabolite of PL69.  Thus, incubating PL16 would show whether further 
metabolism would occur. 
 
 
Figure 8: Structures of PL69 and PL16, two RCQs. 
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PL69 porphyrin incubations - Two PL69 incubations were conducted at varying 
incubation lengths, 30 or 60 minutes. The incubation solution before adding the 
hydrogen peroxide consisted of 70 mM formic acid, 7.8% acetonitrile, 4.5 mg/mL PL69, 
and 1.5 mg/mL Fe(III)TPPS for the 60 minute incubation, and 6.6 mg/mL PL69 and 1.2 
mg/mL Fe(III)TPPS for the 30 minute incubation, all in a total volume of 5 mL.  This 
solution was placed in a foil wrapped Erlenmeyer flask, put in a 50oC water bath, and 
allowed to equilibrate for a few minutes.  Hydrogen peroxide (30%) was added to 
initiate the reaction making the solution, initially, 3% hydrogen peroxide.  The solution 
was incubated for 30 or 60 minutes with intermittent stirring.  Sodium hydroxide (100 
mM) was added to bring the solution to above pH 10.  Dichloromethane (DCM) was 
used to extract the products from the solution.  The DCM was removed using a rotary 
evaporator.  A drying agent as not used with the DCM because the products were run 
through the HPLC for purification and didn’t need to be completely pure at this point. 
PL16 porphyrin incubation - The incubation solution before adding the hydrogen 
peroxide consisted of 70 mM formic acid, 7.8% acetonitrile, 5.6 mg/mL PL16, and 1.8 
mg/mL Fe(III)TPPS in distilled water.  This solution was placed in a foil wrapped 
Erlenmeyer flask, put in a 50oC water bath, and allowed to equilibrate for a few minutes.  
Hydrogen peroxide (30%) was added and the solution was incubated for 45 minutes 
with intermittent stirring.  The same method of extraction as used for the PL69 
porphyrin incubations was used for the PL16 incubations.  
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High performance liquid chromatography - HPLC was used to do initial analysis of the 
incubation solutions as well as to separate the products.  The HPLC used was a dual 
pump Varian Prostar 210 solvent delivery module model, and the processing software 
was Galaxie Chromatography.  Attached was a Varian Prostar 325 dual wavelength 
UV/VIS detector, set at 254 and 280 nm.  A Varian Prostar 701 fraction collector was 
attached to the HPLC system in order to collect the fractions of interest. The solvents 
used were HPLC grade water and acetonitrile, both with 0.1% formic acid.  The column 
used was a reversed phase Ascentis C18, 150x4.6mm, 5um.  The gradient used for 
analysis is outlined in Table 5. 
Time (min) % A % B Flow rate (mL/min) 
0 95 5 1.25 
2 95 5 1.25 
10 35 65 1.25 
Table 5: Elution parameters of the HPLC analyses and separations.  A= water with 0.1% formic acid.  B= 
acetonitrile with 0.1% formic acid.  For separating the products, the gradient was modified depending on 
how close the peaks were together and where they eluted, but the column and solvents remained the 
same.  The fraction collector was set to collect each fraction for 30 seconds.  
Analysis 
HPLC- Purity of the fractions obtained from the HPLC were analyzed using the HPLC.  
The retention times were also examined to determine the peaks that were the same 
products.   
NMR Spectroscopy- Structural analysis was done using a Bruker 400 MHz nuclear 
magnetic resonance (NMR) spectrometer, a Bruker 600 MHz NMR was also used in 
some experiments.   
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Mass Spectrometry- Mass analysis was done using the ThermoElectron LTQ-Orbitrap 
Discovery high resolution mass spectrometer at the Portland State University 
BioAnalytical Mass Spectrometry Facility.            
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Results 
 
 There were many products formed in both the microsome and porphyrin 
methods used.  This was evidenced by the many peaks present when the sample was 
run on the HPLC as well as multiple species in NMR spectra and mass spectra.  There 
weren’t high enough quantities of all of the products to collect and obtain good spectra 
on the NMR, but the 9 products produced with the highest yields were analyzed by NMR 
spectroscopy and mass spectrometry.  These nine proposed oxidation products are in 
Figure 9 on the next page.  The elucidation of the each individual product is explained 
on the following pages.  Some of the products were not fully elucidated due to low 
yields or loss during purification, but the base structure for each product was 
determined. 
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Figure 9: Oxidation products of PL69 and PL16 obtained by incubation with rat liver microsomes or a 
porphyrin oxidation system.  Products were elucidated by NMR and mass spectrometry. 
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Product 1 
 
 
 Product 1 (P1) was present in all of the porphyrin incubations using both PL69 
and PL16.  P1 was produced in three incubations, and the 1H NMR spectrum as 
compared to PL69 is shown in Figure 11.  The top spectrum is PL69 and the arrows point 
to the corresponding quinoline peaks in the bottom spectra.  As seen from these 1H 
NMR spectra, all five of the quinoline peaks are present in P1 with fairly similar chemical 
shifts to each other as well as to the PL69 quinoline peaks.  There were no peaks in the 
aliphatic region of this product, indicating that the product was composed of hydrogens 
solely from the quinoline ring.  From the NMR data, it was hypothesized that P1 was 4-
amino-7-chloroquinoline.  Figure 13 lists the average chemical shifts of the P1 obtained 
from the three incubations as compared to 4-amino-7-chloroquinoline.  The average 
was taken because this product was obtained a few times and in each NMR spectrum 
had a slightly different shift.  The chemical shifts and the splitting of the peaks are very 
similar to actual 4-amino-7-chloroquinoline (Figure 12 and 13). 
 Mass spectrometry data was collected for product 1 in each of the three 
incubations to confirm the identity, which is listed in table 6.  The theoretical exact mass 
for the chemical formula with one hydrogen added from using positive ESI (C9H8ClN2) 
Figure 10: Proposed structure of product 1 (P1). 
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was 179.03760.  The product 1 from the three incubations had m/z values very close to 
the theoretical exact mass, with acceptable ppm differences.  Therefore, it was 
confirmed that product 1 is 4-amino-7-chloroquinoline.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: NMR spectra of PL69 in comparison with product 1, 4-amino-7-chloroquinoline.  The 
quinoline hydrogen peaks of PL69 are indicated with letters corresponding to the structure of PL69.  
The arrows show the corresponding hydrogens in the quinoline ring. 
PL69 
MeOD 
P1 
MeOD 
 PL69 
 a                     c                  e                       d                                                                    b 
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Position 
Average 
shift (ppm) 
Theoretical 
shift (ppm) 
Integration Multiplicity 
a 8.25 8.27 1 d 
b 6.72 6.61 1 d 
c 8.15 8.07 1 d 
d 7.54 7.39 1 dd 
e 7.82 7.77 1 d 
Source of Product Obtained m/z Δppm 
theoretical C9H8ClN2 179.03760 n/a 
PL69 with Fe(III)TPPS (1) 179.03702 3.2451 
PL69 with Fe(III)TPPS (2) 179.03619 7.8810 
PL16 with Fe(III)TPPS 179.03687 4.0829 
Table 6: The exact mass of C9H8ClN2 is listed as well as the m/z values obtained for product 1 that was 
collected from the three different incubations.  The Δppm represents the difference between the 
obtained product m/z and the theoretical exact mass, divided by the theoretical mass. 
Figure 13: 1H NMR assignments of product 1 as compared to 4-amino-7-chloroquinoline.  The 
structure on the left shows the assignment of the hydrogens. 
4-amino-7-chloroquinoline 
MeOD 
P1 
MeOD 
Figure 12: 1H NMR spectra of 4-amino-7-chloroquinoline and Product 1.  The peaks of P1 are shifted 
fairly similar to 4-amino-7-chloroquinoline.  There are two peaks at 7.61 and 7.68 ppm that are 
impurities that are also present in other samples.  
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Product 2 
 
 
 Product 2 (P2) is actually two products that were determined from the 
microsomal incubations.  Both have 1H NMR spectra similar to an already known 
compound, PL16.  The two products will be referred to as P2A and P2B.  These products 
were the few isolated compounds from the microsomal incubations.  Shown in Figure 15 
and 16 are the spectra for PL16 (top), P2A (middle), and P2B (bottom).  In the aromatic 
region, P2A and P2B have slightly different shifts from PL16, but very similar shifts to 
each other and the same type of splitting in present.  In the aliphatic region (Figure 16), 
the same shaped peaks are present, but are at different chemical shifts.  The quartet 
seen at 4.11 ppm is the methylene peak of ethyl acetate.  PL16 and P2A have very 
similar shifts for the two triplets and the pentet.  P2B, however, has one triplet shifted 
from 3.74 ppm to 4.24 ppm and the pentet is shifted from 1.98 ppm to 2.11 ppm.  It is 
hypothesized that P2A is PL16 and P2B is a molecule similar to PL16, but possibly with a 
different electron withdrawing group that causes hydrogen “h” to shift farther 
downfield.  The shift changes in the aromatic region could possibly be accounted for by 
pH differences between the samples.  The aromatic protons seem to be highly 
influenced by slight pH changes.        
Figure 14: Proposed structure of product 2 (P2). 
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PL16 
Figure 15: The aromatic regions of PL16, P2A, and P2B.  Notice the similar chemical shifts.  The 
structure of PL16 is above the spectra with labeled hydrogens. 
PL16 
MeOD 
P2A 
MeOD 
P2B 
MeOD 
         a                 c                 e                      d                                                     b 
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Figure 16: The aliphatic regions of PL16, P2A, and P2B.   
PL16 
MeO
D 
P2A 
MeO
D 
P2B 
MeOD 
 h              f                                                                                           g 
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Product 3 
 
 
 Product 3 (P3) was determined to consist of a piperidine, but the exact structure 
is not known.  The 1H NMR spectrum of P3 in D2O and MeOD is shown in the bottom 
two spectra of Figure 18 and the top two spectra are PL69 in CDCl3 and MeOD.  The 
piperidine peaks of PL69 are indicated in the structure of PL69 and the 1H NMR peaks of 
those hydrogens are labeled on spectra.  The relationships of the piperidine peaks of 
PL69 to the peaks of P3 are indicated by arrows.  After obtaining spectra for P3 in D2O 
and MeOD, the four peaks of the hydrogens in the 2- and 3-positions were easily 
identified.  A 1H NMR peak for the single hydrogen in the 4-position has not yet been 
identified for P3.  During one of the many rotoevaporations and dryings to remove extra 
solvent, P3 was lost from the round bottom flask in which it was stored.  No further 
NMR analyses were able to be done in P3 besides 1H NMR spectroscopy and COSY, and, 
unfortunately, a mass spectrum was not obtained for this product.   
 In order to attempt to further elucidate the structure of P3 after having lost the 
product, the 1H NMR spectrum of P3 was compared with two substituted piperidines, 4-
hydroxypiperidine and 4-aminopiperidine (Figure 19).  The 1H NMR spectra of these two 
piperidines didn’t match the spectra obtained for P3.  The splitting observed in the three 
compounds were similar, but the chemical shifts were very different.  Both 4-
Figure 17: Proposed structure of product 3 (P3). 
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aminopiperidine and 4-hydroxypiperidine had well resolved peaks for the hydrogen at 
the 4 position, which is not present in the spectra for P3.  The peaks had much different 
shifts as well.  For the time being, the complete structure of P3 will remain unknown, 
though, it is probable there is a piperidine group.     
 
 
 
 
 
 PL69 
CDCl3 
PL69 
MeOD 
Product 3 
 D2O 
 
Product 3 
MeOD 
 
a & b 
c & d 
e 
a c  b d e 
a    b d c 
Figure 18: The structure of PL69 with the piperidine assignments.  The spectra shows the 1H NMRs of 
PL69 and P3 in different solvents as well as assignments of the peaks with respect to PL69. 
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Position 
Observed 
shift (ppm) 
Integration Multiplicity 
a 3.57 1 dd 
b 2.30 1 dd 
c 3.13 1 td 
d 1.87 1 qd 
e 3.52? ? ? 
Figure 20:  Structure of P3 with letter assignments correlating to the 1H NMR shifts in the table.   
Product 3 
 MeOD 
PL69 
Product 3 
 D2O 
PL69 
4-aminopiperidine 
 D2O 
 
4-hydroxypiperidine 
D2O 
 
  
Figure 19: Comparison of 1H NMRs of P3 with 4-hydroxypiperidine and 4-aminopiperidine, the 
structures of which are shown under the spectra. 
 
34 
 
Product 4 
 
 
Product 4 (P4) was present in all of the PL69 incubations with Fe(III)TPPS and was 
present in large enough quantities to make it easy to collect 1H NMR data with good 
signal to noise ratio (S/N).  Upon collecting this product, running a 1H NMR spectrum, 
and comparing the 1H NMR spectrum of PL69, it was thought that P4 was probably some 
sort of pyridine.  However, the chemical shifts of this product were very different than 
the shifts of the pyridine in PL69; some of the peaks were shifted farther downfield than 
they had been in PL69 (Figure 22).  The hydrogen at the 2-position of the pyridine 
shifted from 7.51 ppm in PL69 to 8.11 ppm inP4, indicating that a more electronegative 
group had been added near that hydrogen.  It was originally thought that this product 
was picolinic acid, which is pyridine with a carboxyl group attached at the 2-position. 
Mass spectrometry data was obtained for P4 giving a mass (m/z=185.07109) that 
was much larger than what would be expected for picolinic acid (exact mass=123.03203 
amu).  To get an m/z of 185.07109 amu, there needed to be two connected pyridine 
rings.  Based on the mass, the chemical formula of M+1 was determined to be C11H9N2O.  
The identity of P4 was postulated to be di(2-pyridyl) ketone.  The ppm differences 
obtained from the P4 are very low and within a reasonable difference (Table 7).   
Figure 21: Proposed structure of product 4 (P4). 
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The carbonyl group attaching the two pyridyl rings caused the hydrogen at the 2-
position to shift drastically downfield and also shifted the other hydrogens slightly 
farther downfield.  A 1H NMR spectrum obtained for known di(2-pyridyl) ketone in 
chloroform was compared to a sample of P4 in chloroform to ensure the structure was 
elucidated correctly.  Those 1H NMR spectra are shown in Figure 23 and listed in Figure 
24.  With the combination of 1H NMR spectra, mass spec, and comparison to a known 
structure, the identity of P4 was determined to be di(2-pyridyl) ketone.       
 
 
 
   
 
 
PL69 
MeOD 
From PL69 w/Fe(III)TPPS (1) 
MeOD 
30 min inc 
From PL69 w/Fe(III)TPPS (2) 
MeOD 
15+30 min inc 
 
From PL69 w/Fe(III)TPPS (3) 
MeOD 
1 hr inc 
 
Figure 22:  The top 1H NMR spectrum is PL69 and the bottom three spectra are P4 from three 
different incubations.  Notice the drastic chemical shift changes of some of the pyridine peaks as 
compared to those of PL69. 
 
 
PL69 
 a                                                        c                 d                  b 
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Source of Product Obtained m/z Δppm 
theoretical C11H9N2O 185.07149 n/a 
P4  [Fe(III)TPPS (30min)] 185.07133 0.86453 
P4 [Fe(III)TPPS (15+30min)] 185.07028 6.4861 
P4 [Fe(III)TPPS (1hr)] 185.07108 2.1916 
Position 
Observed 
shift (ppm) 
Theoretical 
shift (ppm) 
Integration Multiplicity 
a 8.77 8.76 1 dt 
b 7.50 7.49 1 ddd 
c 7.91 7.90 1 ddd 
d 8.11 8.10 1 dt 
Di(2-pyridyl) ketone 
MeOD 
P4 
MeOD 
Figure 23: The top 1H NMR spectrum is di(2-pyridyl) ketone and the bottom spectrum is P4 obtained 
from the 30 minute PL69 incubation with Fe(III)TPPS.  The chemical shifts are basically identical, 
indicating the identity of P4.  There are two impurity peaks at 7.53 and 7.71 ppm. The identity has 
not been elucidated, but they are present in other sample spectra so they were determined to be 
impurities. 
Figure 24: The chemical shifts of P4 (observed shift) as compared with di(2-pyridyl) ketone 
(theoretical shift).  The integration and multiplicity of the peaks are also listed and correlate with 
those of di(2-pyridyl) ketone. 
Table 7: Mass spectra data obtained for P4 from three different incubations.  The top row, C11H9N2O, 
is the theoretical exact mass of P4+H, which would be seen in the positive mode mass spectrum. 
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Product 5 
 
 
 Product 5 (P5) is similar to M9 seen in the incubations done by WuXi AppTec, 
except M9 has a hydroxyl at the 4-position of the piperidine rather than an amine.  This 
product was not isolated during the initial porphyrin incubations, but was isolated in two 
of the more recent porphyrin incubations.  The 1H NMR spectrum of P5 is similar to that 
seen for PL69, except the pyridyl peaks were missing from the aromatic region (Figure 26 
and 27).  The mass spectrum (Figure 28) obtained for P5 had an M+1 of 319.16736 amu, 
with a difference of only 5 ppm from the theoretical mass of C17H24N4Cl (319.16895 amu).  
Based on the presence of the same peaks in the aromatic and aliphatic region as PL69 as 
well as factoring in the mass, the P5 was determined to be N-(3-(4-aminopiperidin-1-
yl)propyl)-7-chloroquinolin-4-amine.     
 
 
Figure 25: Proposed structure of product 5 (P5). 
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Product 5 
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Figure 26: Comparison of 1H NMR spectra of PL69 (top) and P5 (bottom).  The same quinoline peaks 
are present in P5 as in PL69. 
Figure 27: Comparison of the aliphatic region of PL69 (top) and P5 (bottom).  The same peaks are 
present in P5, but slightly shifted compared to PL69.   
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15 min 7-8 #1 RT: 0.00 AV: 1 NL: 1.92E6
T: FTMS + p ESI Full ms [50.00-2000.00]
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Figure 28: Mass spectrum of P5. 
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Product 6 
 
 
 Product 6 (P6) proved to be a tricky compound to elucidate.  Proton NMR 
spectra as well mass spectra have been obtained for P6, but the puzzle of the complete 
structure has not been determined.  The 1H NMR spectrum for this product in MeOD 
gave five peaks in the aromatic region (Figure 30) and no other peaks.  By looking at the 
chemical shifts of P6 in comparison to PL69, P6 was determined to contain at least one 
pyridine ring.  To try to see any exchanging protons, P6 was run on the NMR in 
deuterated dimethyl sulfoxide (DMSO-d6), which gave very broad peaks.  Sodium 
deuteroxide (NaOD) was added to the DMSO-d6 sample to try to get sharper peaks, 
even though adding NaOD introduced water to the sample, removing the exchanging 
proton peaks.  Adding NaOD sharpened up the peaks quite a bit, but also started to 
oxidize the sample.  Every 1H NMR spectra obtained after adding NaOD made the P6 
peaks smaller and some other peaks larger, including peaks corresponding to P4, di(2-
pyridyl) ketone (Figure 30).  There seems to be oxidation of P6 to other products besides 
just P4, as well.  
 A mass spectrum was obtained for P6 which gave an m/z in the positive mode of 
169.07507 amu, corresponding to a chemical formula of C11H9N2 (Figure 32).  The ppm 
Figure 29: Proposed structure of product 6 (P6). 
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difference between the m/z and the exact mass of C11H9N2 is 9 ppm.  This formula 
corresponds to the actual m/z, rather than the M+1, because there was not a structure 
that could be identified, that made sense, for a formula of C11H8N2.  The m/z obtained 
from the mass spectrum led to the belief that P6 has two pyridine rings.  Multiple 
structures were examined in order to try to get a product with just one pyridine ring, 
but those structures always added in more hydrogens that weren’t present in the 1H 
NMR spectrum.  It is probable that the molecule fragmented upon entering the mass 
spectrometer giving a structure shown in Figure 31.  This structure fits with the mass 
obtained, but is most likely just a fragment of the actual molecule of P6.  One 
explanation could be a hydroxyl group attached to the carbon linking the two pyridyl 
rings which broke off upon entering the MS.  Adding NaOD to the NMR sample would 
have neutralized the acid and added hydroxide ions that could oxidize the molecule.  
 
 
 
 
Product 6 
MeOD 
Product 6 
DMSO+NaOD 
Product 4 
MeOD 
Figure 30: The top spectrum is P6 in deuterated methanol.  The middle spectrum is P6 in DMSO with 
NaOD, a few days after adding NaOD.  The bottom spectrum is P4, which seems to be present in the 
middle spectrum. 
42 
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Figure 31: Possible explanation of P6 fragment measured by the MS.  The positive charge could be 
stabilized by the aromatic rings.   
Figure 32: Mass spectrum of P6 
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Product 7 
 
 
The full identity of product 7 (P7) has not been fully elucidated, but the pieces of 
this product are known.  The 1H NMR spectrum of P7 has four peaks in the aromatic 
region (Figure 34).  The three hydrogens on the ring with the chlorine have similar peaks 
as seen in the 1H NMR spectrum of PL69.  However, there is only one peak present in 
the spectrum to represent the hydrogens on the ring with the nitrogen.  Sometimes, the 
hydrogen at the 2-position is not seen in the 1H NMR spectrum, depending on solvent, 
but the hydrogen at the 3-position would still be seen as a doublet, so it can be assumed 
the 2-position hydrogen was present.  However, in the case of this product, there is no 
hydrogen in the area of the hydrogen at the 3-position, but there was a singlet slightly 
up field from where the hydrogen at the 2-position usually is, leading to the belief that 
there was a substitution at the 3-position. The j-values calculated for the spectrum of P7 
in the aromatic region were similar to those of PL16, which lead to the peak 
assignments.  The aliphatic peaks of P7 correspond to those seen in the aliphatic region 
of PL16 (Figure 35).   
Figure 33: Proposed structure of product 7 (P7). 
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 There were three peaks seen in the aliphatic region that correlated to the three 
carbon chain attached to the chloroquinoline ring.  There didn’t seem to be any other 
hydrogens attached to carbons present in the 1H NMR spectrum.  The identity of the “R” 
group at position three of the ring was not elucidated.  The product was, unfortunately, 
lost before obtaining a mass spectrum.        
        
 
 
 
 
Figure 34: The aromatic region of P7 as compared to PL16 (top spectrum).  There is a loss of the 
doublet at 6.5 ppm and the doublet at 8.35 ppm, but there is a singlet at 8.1 ppm. 
PL16 
MeOD 
Product 7 
CDCl3 
PL69 
CDCl3 
 
PL69 
PL16 
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45 
 
 
Figure 35: The aliphatic region of P7 as compared to PL16 (top spectrum).  The P7 peak peak at 3.64 is 
a quartet because the solvent is CDCl3 and the hydrogens of that peak are seeing the –NH attached to 
the quinoline ring.  The triplet at 2.54 is considered an impurity because it does not integrate with the 
other peaks.  It could possibly be from another product in the sample. 
PL16 
MeOD 
Product 7 
CDCl3 
PL69 
CDCl3 
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Product 8 
 
 
 Product 8 (P8) was only analyzed by mass spectrometry, there was not enough 
to obtain a 1H NMR spectrum.  It was obtained in a pure form, but was present in the 
mass spectrum of some of the other products, including P5.  The structures resembles 
M9 from the metabolism of PL69 completed by WuXi AppTech (Figure 7) with a carbonyl 
added in place of two hydrogens.  The ppm difference between the m/z and the 
C17H21N3O2Cl (M+1) is just 5 ppm, which means this formula is probably correct.  The full 
structure cannot be known without NMR data, but the structure above is a probable 
structure based on the mass spec data.    
Figure 36: Proposed structure of product 8 (P8). 
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Product 9 
 
 
 Product 9 (P9) has a theoretical structure similar to P5, except with an added 
carbonyl in place of a methylene group.  There was not enough of this product to obtain 
a well resolved 1H NMR spectrum, so it was only analyzed by MS.  This type of structure 
would probably make the piperidine ring open and an aldehyde form, which is one of 
the few ways a methylene group can be removed without breaking the molecule.  
Another possible structure is formation of an ether at the 2- or 3-position of the 
piperidine.  Possible structures are on the next page in Figure 38.  The exact mass of 
M+1 is 321.14821 amu, which is a ppm difference of 6 ppm compared to the m/z 
obtained, 321.14639 amu.    
Figure 37: Proposed structure of product 9 (P9). 
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Figure 38: Possible structures for P9 to fit the chemical formula C11H21N4OCl. 
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Discussion 
 
 Oxidation of a reversed chloroquine, PL69, with Fe(III)TPPS allowed for analysis 
of oxidation products that are similar to the products obtained with in vitro metabolism 
methods.  It was hypothesized the products of the porphyrin oxidations would be 
similar to those of in vitro methods, but the degree of similarity for PL69 was not known.  
The results discussed in this thesis show that, although some of the products of the 
porphyrin oxidations were slightly different than those found in the metabolism with 
microsomes, they provided a reasonable starting point for metabolism analysis.  The 
most prominent reaction that occurred was N-dealkylation, but hydroxylation and 
oxidation were also seen. 
Looking at the metabolite structures proposed by WuXi AppTec, comparisons 
can be made between the structures determined with Fe(III)TPPS and the structures 
determined with the rat, monkey, and human liver microsomes.  Shown in Figure 40 (at 
the end of this section) are the structures of the metabolites formed by microsomes 
(red), as determined by WuXi AppTec, and the structures determined from the 
porphyrin oxidations (blue).  When comparing side by side, many similarities are seen in 
the products of the microsome and porphyrin incubations.  The microsomal incubations 
by WuXi AppTech included more dealkylations with addition of oxygen (hydroxyl or 
carbonyl), than what was seen with the porphyrin oxidations.  This could possibly be due 
to higher oxidizing capabilities of CYP450s.  P1 and P5 were all formed in the porphyrin 
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incubations, as well as the microsomal incubations by WuXi AppTech.  This indicates 
that the porphyrin method provides products that are similar, if not the same, as what 
would be expected in microsomal incubations.  
 Many oxidation products were produced from reacting PL69 with microsomes 
as well as with the iron porphyrin and hydrogen peroxide.  Difficulty was encountered 
when trying to separate and analyze all of the products from one another, but the main 
products obtained were analyzed by NMR spectroscopy and/or mass spectrometry.  A 
total of ten products were analyzed from incubations with PL69 and PL16 (a known 
metabolite of PL69).  Unfortunately, some of the products were only analyzed by one 
method, either because they were produced in a small amount or the product was lost.  
Even though not all of the products were fully elucidated, the suggested structures 
provide a good framework for examining oxidation processes of other compounds with 
a porphyrin incubation.      
There are multiple options for the next steps.  First, another microsomal 
incubation could be done with PL69 now that there is a better method for separation of 
the compounds, in order to compare the products from both methods.  Another option 
is to use the porphyrin system to examine the oxidation products of other reversed 
chloroquines.  This same porphyrin system has been used to study one other compound 
from the Peyton lab, PL241, by Tess Harris (Figure 39).  PL241 has a 4-amino-7-
chloroquinoline group on both sides of the molecule and produced only four oxidation 
products, making it much easier to study than PL69.  The products seen in oxidation of 
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PL241 followed the same patterns as seen for PL69, with the most prominent reaction 
being N-dealkylation.  Once the identity of the in vitro or in vivo metabolites are fully 
known, the next step would be to examine toxicity as well as efficacy of each of the 
metabolites.  This would probably include synthesizing the prominent metabolites and 
then testing them for activity and toxicity.   
 
Since the porphyrin system produced similar products as what was predicted in 
the microsomal incubations, this system could be used to develop an understanding of 
possible metabolites for multiple compounds before investing in the more expensive 
microsomal incubations.  The porphyrin method at least could provide a framework for 
understanding what type of metabolism might occur in vivo.  The process of separation 
and data collection could be improved to provide a much quicker, more efficient 
method to examine the products.  Overall, using Fe(III)TPPS seemed to be a suitable 
mimic of CYP450 in that it produced similar products to those seen with CYP450.  This 
method should be examined with other reversed chloroquines to determine the 
accuracy of oxidation as compared to microsomes and other sources of CYP450. 
 
Figure 39: Structure of PL241. 
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Figure 40: Comparison of the metabolites of PL69 determined by WuXi AppTech (red) with 
the products from this research that were elucidated by mimicking metabolism with 
microsomes and a metalloporphyrin system (blue).  The oxidation products in blue are 
similar to the metabolites in red.  This shows that using a metalloporphyrin system can 
provide a framework for understanding metabolism of a drug. 
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Appendix A: NMR spectra of PL69  
 
NMR spectra of PL69 in deuterated methanol 
400 NMR 
1H NMR # of scans=16 
13C NMR # of scans=256 
 
 
Assignment 1H shift (ppm) Multiplicity Integration 13C shift (ppm) 
a - - - 162.17 
b - - - 152.71 
c 8.34 d 1 152.47 
d 8.5 dq 2 149.98 
e - - - 149.63 
f 7.76 ddd 2 138.62 
g - - - 136.31 
h 7.77 d 1 127.63 
i 7.44 ddd 1 126.09 
j 8.03 d 1 124.29 
k 7.53 d 2 124.06 
l 7.26 ddd 2 123.94 
m - - - 118.75 
n 6.49 d 1 99.59 
o 5.24 s 1 66.59 
p 2.44 t 2 57.63 
q 2.4 m 1 53.87 
r 2.95 d 2 53.5 
r' 1.92 m 2 53.5 
s 3.36 t 2 42.89 
t 1.95 m 2 33.01 
t' 1.55 m 2 33.01 
u 1.91 m 2 26.13 
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Appendix B: NMR spectra of PL16 
 
NMR spectra of PL16 in deuterated methanol 
400 NMR 
1H NMR # of scans=16 
13C NMR # of scans=256 
 
Assignment 1H shift (ppm) Multiplicity Integration 13C shift (ppm) 
a - - - 152.86 
b 8.34 d 1 152.22 
c - - - 149.41 
d - - - 136.39 
e 7.77 d 1 127.41 
f 7.39 dd 1 126.03 
g 8.05 d 1 124.24 
h - - - 118.71 
i 6.54 d 1 99.58 
j 3.74 t 2 60.77 
k 3.47 t 2 41.26 
l 1.96 p 2 32.12 
Assignment of PL16 NMR chemical shifts 
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Appendix C: NMR spectra of oxidation products 
 
NMR spectra of P1 in MeOD 
30 minute PL69 porphyrin incubation: 
400 NMR 
1H NMR # of scans= 16 
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30 minute PL16 incubation: 
400 NMR 
1H NMR # of scans= 256 
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NMR spectra of P2A and P2B 
400 NMR 
1H NMR # of scans= 512 
 
P2A in MeOD: 
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P2B in MeOD: 
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NMR spectra of P3  
In MeOD: 
400 NMR 
1H NMR # of scans= 16 
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In D2O: 
400 NMR 
1H NMR # of scans= 256 
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Spectra of P4 in MeOD 
400 NMR 
1H NMR # of scans=16 
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NMR spectra of P5 in MeOD 
400 NMR 
1H NMR # of scans= 1024 
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NMR spectra of P6 
In MeOD: 
400 NMR 
1H NMR # of scans= 1024 
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In DMSO-d6: 
400 NMR 
1H NMR # of scans= 1024 
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In DMSO-d6 with NaOD: 
400 NMR 
1H NMR # of scans= 1024 
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NMR spectra of P7 in CDCl3 
400 NMR 
1H NMR # of scans= 256 
 
 
81 
 
 
 
82 
 
 
